N4 Pharma (GB:N4P) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
N4 Pharma has filed a new patent for its innovative oral anti-inflammatory product targeting Irritable Bowel Disease (IBD) using its proprietary Nuvec® delivery system. The product aims to replace current treatments with significant side effects by utilizing nanoparticles to deliver RNA that inhibits inflammation and boosts natural defenses in the gut. This development highlights N4 Pharma’s commitment to advancing RNA therapeutics and attracting potential investors and collaborators.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
